

Index

Note: Page numbers of article titles are in **boldface** type.

A

Abdomen, acute surgical, 319–322

Acinetobacter infection

- bacteria associated with, 237–238
- in ICU, **237–248**
 - antimicrobial resistance to, 239–240
 - epidemiology of, 238–239
 - infection control, 243
 - treatment of, antibiotics in, 241–243
 - virulence of, 239

Acute bacterial endocarditis

- MSSA and MRSA, vancomycin for, 405–406
- nosocomially-acquired. See also *Catheter-related bloodstream infections (CR-BSIs)*.
 - empiric therapy for, **293–312**

Acute surgical abdomen, 319–322

Allergy(ies)

- defined, 421–422
- penicillin, empiric antimicrobial therapy for septic patients with, 328–330

Anaphylaxis, antibiotics and, 422–424

Anemia, antibiotics and, 426

Antibiotic(s)

- adverse reactions to, **421–433**
 - anaphylaxis, 422–424
 - anemia, 426
 - antibiotic-resistant superinfections, 433
 - cardiotoxicity, 424
 - coagulation, 427
 - colitis, 432–433
 - dermatological, 427–429
 - diarrhea, 432–433
 - electrolyte and glucose abnormalities, 431
 - fever, 431–432
 - hematological, 426–427
 - hepatotoxicity, 430–431

leukopenia, 426

- musculoskeletal toxicity, 431
- nephrotoxicity, 424–426
- neurotoxicity, 429–430
- ototoxicity, 429–430
- rashes, 427–428

“red man” syndrome, 428–429

- Stevens-Johnson syndrome, 428
- thrombocytopenia, 426–427
- bactericidal, in critical care medicine, value of, 358–359
- concentration-dependent-killing, application of, 339–340
- dose-dependent-killing, clinical application of, 339–340
- drug interactions with, **433–437**
 - beneficial, 434–435
 - harmful, 435–437
- empiric, for septic shock and sepsis, **313–334**. See also *Sepsis*; *Septic shock*.
- for *Acinetobacter* infection in ICU, 241–243
- for MRSA, in critical care, **249–260**. See also *Methicillin-resistant Staphylococcus aureus (MRSA)*, *antibiotic therapy of, in critical care*.

Antimicrobial agents. See *Antibiotic(s)*.

Arteriovenous shunt infections, MSSA and MRSA, vancomycin for, 404–405

B

Bacteremia, daptomycin for, 355–357

Bacteremia(s), MSSA and MRSA, vancomycin for, 401–403

Bacteremia/sepsis, colistin in, administration of, 383

Bacteria, killing of, anti-infective agents in, mode of, 337

Bacterial endocarditis, acute
MSSA and MRSA, vancomycin for, 405–406

- Bacterial endocarditis (*continued*)
 nosocomially-acquired, empiric
 therapy for, **293–312**
- Bactericidal antibiotics, in critical care
 medicine, value of, 358–359
- Bioavailability, in
 pharmacokinetics/pharmacodynamics,
 344–345
- Biofilms, activity in, 359
- Bloodstream infections, catheter-related,
293–312. See also *Catheter-related
 bloodstream infections (CR-BSI)*.
- Bone(s), as sepsis source, 319

C

- Cardiotoxicity, antibiotics and, 424
- Catheter-related bloodstream infections
 (CR-BSIs), **293–312**
 management of
 duration of, 300–301
 empiric therapy in, 298–299
 in ICU patients, 294–296
 lock therapy in, 302–303
 new drugs in, 299–300
 retaining vs. removing catheter
 in, 296–298
 vs. prevention, 303–305
 microorganisms causing, 296
 ruling out, 301–302
 suspicion of, 301–302
- Central intravenous line infections, MSSA
 and MRSA, vancomycin for, 403–404
- Central nervous system (CNS) infections,
 staphylococcal, vancomycin for,
 406–407
- Central venous catheters (CVCs)
 prevalence of use of, 293
 sepsis due to, 315
- Clearance, in
 pharmacokinetics/pharmacodynamics,
 343
- Clindamycin, for MRSA infections, 257
- Clostridium difficile* colitis
 in critical care setting
 diagnosis of, 284–285
 treatment of, **279–291**
 blocking toxin
 activity-related, 283
 metronidazole in, 281–282
 nitazoxanide in, 282
 OPT-80 in, 283
 practical hints in, 285–286

- rifaximin in, 282–283
 stopping antibiotic in, 280
 surgical, 285
 vancomycin in, 280–281
 recurrent, management of, 286–287
- Coagulation, antibiotics and, 427
- Colistin
 adverse effects of, 384–385
 for *Pseudomonas aeruginosa*, 265–272
 adverse reactions, 270–271
 antibacterial activity of, 266–267
 clinical experience with,
 268–270
 dosage schedules for, 267–268
 mode of action of, 265–266
 resistance development, 271
 toxicity of, 270–271
 forms of, 378–379
 in bacteremia/sepsis, administration
 of, 383
 in critical care, **377–391**
 administration of, 381–382
 routes of, 384
 dosage of, 380–381
 in meningitis, administration of,
 383–384
 in ventilator-associated pneumonia,
 administration of, 382–383
- Colitis
 antibiotics and, 432–433
Clostridium difficile, in critical care
 setting, treatment of, **279–291**.
 See also *Clostridium difficile
 colitis, in critical care setting,
 treatment of*.
- CR-BSIs. See *Catheter-related bloodstream
 infections (CR-BSIs)*.
- Critical care clinicians,
 pharmacokinetics/pharmacodynamics
 for, **335–348**. See also
*Pharmacokinetics/pharmacodynamics,
 for critical care clinicians*.

D

- Dalbavancin, for CR-BSIs, 300
- Daptomycin
 for bacteremia, 355–357
 for CR-BSIs, 299–300
 for endocarditis, 355–357
 for MRSA infections, 254–255
 for *Staphylococcus aureus* infections, in
 critical care medicine, **349–363**
 clinical data related to, 354–357
- Dermatological adverse reactions, 427–429

Download English Version:

<https://daneshyari.com/en/article/3108606>

Download Persian Version:

<https://daneshyari.com/article/3108606>

[Daneshyari.com](https://daneshyari.com)